Biocryst Pharmaceuticals (BCRX) Receivables - Net (2010 - 2026)
Biocryst Pharmaceuticals' (BCRX) quarterly Receivables - Net came in at $109.3 million in Q1 2026, up 17.0% YoY from $93.4 million in Q1 2025, and up 2.3% on a QoQ basis from $106.8 million in Q4 2025.
Biocryst Pharmaceuticals (BCRX) Receivables - Net (2010 - 2026) Analysis & Trends
Biocryst Pharmaceuticals (BCRX) has 17 years of Receivables - Net data on file, last reported at $109.3 million in Q1 2026.
- Quarterly Receivables - Net rose 17.0% year-over-year to $109.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $109.3 million (up 17.0% YoY) and the FY2025 annual result came in at $106.8 million, up 35.09% from the prior year.
- Receivables - Net advanced to $109.3 million in Q1 2026, from $106.8 million in the prior quarter.
- In the past five years, Receivables - Net ranged from a high of $109.3 million in Q1 2026 to a low of $36.4 million in Q1 2022.
- A 5-year average of $67.6 million and a median of $60.6 million in 2024 frame the typical range for Receivables - Net.
- Annual changes were most pronounced in 2022 — Receivables - Net soared 1996.36% — and 2026, when it increased 17.0%.
- Tracing BCRX's Receivables - Net over 5 years: stood at $41.5 million in 2022, then soared by 37.2% to $57.0 million in 2023, then soared by 33.95% to $76.3 million in 2024, then jumped by 40.03% to $106.8 million in 2025, then advanced by 2.3% to $109.3 million in 2026.
- The last three Receivables - Net figures came in at $109.3 million (Q1 2026), $106.8 million (Q4 2025), and $91.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.83 Bn | 42.86 Bn | - |
| 2 | Teva Pharmaceutical Industries | 42.87 Bn | 39.22 Bn | 2.15 Bn |
| 3 | Zoetis | 31.41 Bn | 29.73 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.55 Bn | 22.75 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.08 Bn | 19.42 Bn | 683.80 Mn |
| 6 | Viatris | 18.73 Bn | 17.84 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.44 Bn | 15.05 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.75 Bn | 11.22 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.11 Bn | 9.94 Bn | - |
| 10 | Biocryst Pharmaceuticals | 2.46 Bn | 2.11 Bn | 214.41 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 110.76 Mn |
| Jun 30, 2026 | 110.76 Mn |
| Mar 31, 2026 | 109.27 Mn |
| Mar 31, 2026 | 109.27 Mn |
| Dec 31, 2025 | 106.82 Mn |
| Dec 31, 2025 | 106.82 Mn |
| Sep 30, 2025 | 91.33 Mn |
| Sep 30, 2025 | 91.33 Mn |
| Jun 30, 2025 | 91.18 Mn |
| Jun 30, 2025 | 91.18 Mn |
| Mar 31, 2025 | 93.39 Mn |
| Mar 31, 2025 | 93.39 Mn |
| Dec 31, 2024 | 76.28 Mn |
| Dec 31, 2024 | 76.28 Mn |
| Sep 30, 2024 | 72.46 Mn |
| Sep 30, 2024 | 72.46 Mn |
| Jun 30, 2024 | 68.76 Mn |
| Jun 30, 2024 | 68.76 Mn |
| Mar 31, 2024 | 60.59 Mn |
| Mar 31, 2024 | 60.59 Mn |